



# Gliotoxin, a Known Virulence Factor in the Major Human Pathogen *Aspergillus fumigatus*, Is Also Biosynthesized by Its Nonpathogenic Relative *Aspergillus fischeri*

 Sonja L. Knowles,<sup>a</sup>
 Matthew E. Mead,<sup>b</sup>
 Lilian Pereira Silva,<sup>c</sup>
 Huzefa A. Raja,<sup>a</sup>
 Jacob L. Steenwyk,<sup>b</sup>  
 Gustavo H. Goldman,<sup>c</sup>
 Nicholas H. Oberlies,<sup>a</sup>
 Antonis Rokas<sup>b</sup>

<sup>a</sup>Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, North Carolina, USA

<sup>b</sup>Department of Biological Sciences, Vanderbilt University, Nashville, Tennessee, USA

<sup>c</sup>Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil

**ABSTRACT** *Aspergillus fumigatus* is a major opportunistic human pathogen. Multiple traits contribute to *A. fumigatus* pathogenicity, including its ability to produce specific secondary metabolites, such as gliotoxin. Gliotoxin is known to inhibit the host immune response, and genetic mutants that inactivate gliotoxin biosynthesis (or secondary metabolism in general) attenuate *A. fumigatus* virulence. The genome of *Aspergillus fischeri*, a very close nonpathogenic relative of *A. fumigatus*, contains a biosynthetic gene cluster that is homologous to the *A. fumigatus* gliotoxin cluster. However, *A. fischeri* is not known to produce gliotoxin. To gain further insight into the similarities and differences between the major pathogen *A. fumigatus* and the nonpathogen *A. fischeri*, we examined whether *A. fischeri* strain NRRL 181 biosynthesizes gliotoxin and whether the production of secondary metabolites influences the virulence profile of *A. fischeri*. We found that *A. fischeri* biosynthesizes gliotoxin under the same conditions as *A. fumigatus*. However, whereas loss of *laeA*, a master regulator of secondary metabolite production (including gliotoxin biosynthesis), has previously been shown to reduce *A. fumigatus* virulence, we found that *laeA* loss (and loss of secondary metabolite production) in *A. fischeri* does not influence its virulence. These results suggest that *LaeA*-regulated secondary metabolites are virulence factors in the genomic and phenotypic background of the major pathogen *A. fumigatus* but are much less important in the background of the nonpathogen *A. fischeri*. Understanding the observed spectrum of pathogenicity across closely related pathogenic and nonpathogenic *Aspergillus* species will require detailed characterization of their biological, chemical, and genomic similarities and differences.

**IMPORTANCE** *Aspergillus fumigatus* is a major opportunistic fungal pathogen of humans, but most of its close relatives are nonpathogenic. Why is that so? This important, yet largely unanswered, question can be addressed by examining how *A. fumigatus* and its close nonpathogenic relatives are similar or different with respect to virulence-associated traits. We investigated whether *Aspergillus fischeri*, a nonpathogenic close relative of *A. fumigatus*, can produce gliotoxin, a mycotoxin known to contribute to *A. fumigatus* virulence. We discovered that the nonpathogenic *A. fischeri* produces gliotoxin under the same conditions as those of the major pathogen *A. fumigatus*. However, we also discovered that, in contrast to what has previously been observed in *A. fumigatus*, the loss of secondary metabolite production in *A. fischeri* does not alter its virulence. Our results are consistent with the “cards of virulence” model of opportunistic fungal disease, in which the ability to cause disease stems from the combination (“hand”) of virulence factors (“cards”) but not from individual factors *per se*.

**Citation** Knowles SL, Mead ME, Silva LP, Raja HA, Steenwyk JL, Goldman GH, Oberlies NH, Rokas A. 2020. Gliotoxin, a known virulence factor in the major human pathogen *Aspergillus fumigatus*, is also biosynthesized by its nonpathogenic relative *Aspergillus fischeri*. mBio 11:e03361-19. <https://doi.org/10.1128/mBio.03361-19>.

**Editor** Yong-Sun Bahn, Yonsei University

**Copyright** © 2020 Knowles et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Gustavo H. Goldman, [ggoldman@usp.br](mailto:ggoldman@usp.br), Nicholas H. Oberlies, [nicholas\\_oberlies@uncg.edu](mailto:nicholas_oberlies@uncg.edu), or Antonis Rokas, [antonis.rokas@vanderbilt.edu](mailto:antonis.rokas@vanderbilt.edu).

This article is a direct contribution from a Fellow of the American Academy of Microbiology. Solicited external reviewers: Sean Doyle, Maynooth University, Ireland; Jin Woo Bok, University of Wisconsin—Madison.

**Received** 20 December 2019

**Accepted** 3 January 2020

**Published** 11 February 2020

**KEYWORDS** fungal pathogenesis, secondary metabolism, gliotoxin, specialized metabolism, evolution of virulence, *laeA*, aspergillosis


*Aspergillus fumigatus* is a major fungal pathogen responsible for hundreds of thousands of infections and deaths each year (1, 2). Several secondary metabolites biosynthesized by *A. fumigatus* have been shown to be required for disease (3). For example, gliotoxin (Fig. 1A), a secondary metabolite that belongs to the epipolythiodioxopiperazine (ETP) class of mycotoxins (4–6), can be detected in the sera of patients with invasive aspergillosis (7) and is known to inhibit the host immune response (3). When the *gliP* gene, which encodes the essential nonribosomal peptide synthetase of the gliotoxin biosynthetic gene cluster, is deleted from *A. fumigatus*, the mutant strain does not biosynthesize gliotoxin and exhibits attenuated virulence in a nonneutropenic murine model of aspergillosis (8–10). Similarly, deletion of *laeA*, a positive regulator of several *A. fumigatus* secondary metabolites, including gliotoxin, also reduces virulence (11, 12). These results suggest that gliotoxin, as well as other secondary metabolites, contributes to *A. fumigatus* virulence (3).

Even though *A. fumigatus* is a major pathogen, its closest relatives are nonpathogenic (13–15). For example, the closely related species *Aspergillus fischeri* has been identified as the cause of only a few clinical cases (16, 17) and is not considered pathogenic. Detailed comparisons of levels of virulence in diverse murine and invertebrate models of fungal disease have shown that *A. fischeri* is much less virulent than *A. fumigatus* (14). It is important to emphasize here that nonpathogens can sometimes cause disease in diverse animal models of aspergillosis, especially when high inoculums of spores are administered, as we have observed in previous experiments with *A. fischeri*; however, in all such cases, nonpathogens exhibit lower levels of virulence than pathogens (14).

Despite significant differences in their abilities to cause disease, a recent examination of known genetic contributors to virulence revealed that nearly all genes known to contribute to *A. fumigatus* disease are also present in *A. fischeri* (14). For example, both species appear to contain *laeA*, and deletion of the *laeA* gene from either species reduces the biosynthesis of secondary metabolites (14, 18), suggesting that the gene's function is conserved. Similarly, both species appear to contain intact gliotoxin biosynthetic gene clusters (Fig. 1B); however, while gliotoxin production has been shown in *A. fumigatus* and a few other closely related species (19), it has not been reported to be produced by *A. fischeri* (14, 19). These data raise two questions: is *A. fischeri* capable of biosynthesizing gliotoxin, and if it is, how does the production of gliotoxin, and secondary metabolites more generally, influence its virulence profile?

***A. fischeri*, a nonpathogenic relative of the major pathogen *A. fumigatus*, can also biosynthesize gliotoxin.** To test whether *A. fischeri* biosynthesizes gliotoxin, we examined the chemical profile of a standard of gliotoxin, an extract of *A. fumigatus* strain Af293, and an extract of *A. fischeri* strain NRRL 181 via ultrahigh-performance liquid chromatography–high-resolution electrospray ionization mass spectrometry (UHPLC–HRESIMS). We collected three sets of data: chromatographic retention time, high-resolution mass spectrometry data, and tandem mass spectrometry fragmentation patterns. Analysis of a gliotoxin standard (Fig. 1C) showed that it elutes at 3.30 min with an accurate mass of 327.0464 Da (2.8 ppm) and has key fragments of 263.1 Da and 245.1 Da, in accord with values reported in the literature (20).


We next analyzed *A. fumigatus* strain Af293 as a positive control since it is known to biosynthesize gliotoxin (19). When *A. fumigatus* was grown on Czapek–Dox agar (CDA) at 37°C (Fig. 1D), a peak with the same retention time (3.30 min), HRESIMS spectrum, MS/MS spectrum, and accurate mass of 327.0463 (3.1 ppm) as the gliotoxin standard was noted (Fig. S1 and S2). We also detected gliotoxin production, albeit in lower abundance, when we cultured *A. fumigatus* on 5% blood agar at 37°C (Fig. 1E). In contrast, we did not observe gliotoxin production when we grew *A. fumigatus* on oatmeal agar (OMA) at 37°C (Fig. S3).



**FIG 1** *Aspergillus fischeri* biosynthesizes gliotoxin when grown under conditions that induce *A. fumigatus* gliotoxin biosynthesis. (A) Chemical structure of gliotoxin. (B) The genome of the nonpathogenic species *A. fischeri* strain NRRL 181 (14, 28) contains a biosynthetic gene cluster homologous to the gliotoxin cluster in the major pathogen *A. fumigatus* strain Af293 (4–6). Arrows indicate genes and the direction in which they are transcribed. Homologous genes are connected by gray parallelograms. (C to I) Chromatograms demonstrating the biosynthesis of gliotoxin in *A. fischeri* when grown on CDA or blood agar at 37°C. Each sample (dried organic extract in MeOH at a concentration of 0.2 mg/ml) was analyzed by UHPLC-HRESIMS, and the data are presented as extracted ion chromatograms (XIC) using the protonated mass of gliotoxin ( $C_{13}H_{15}N_2O_5S_2$ ;  $[M+H]^+ = 327.0473$ ) and a window of  $\pm 5.0$  ppm. (C) Analysis of the gliotoxin standard (in MeOH at a concentration of 0.01 mg/ml). (D) *A. fumigatus* grown on CDA at 37°C. (E) *A. fumigatus* grown on blood agar at 37°C. (F) *A. fischeri* grown on CDA incubated at 37°C. (G) *A. fischeri* grown on blood agar incubated at 37°C. (H) *A. fischeri* grown on CDA at room temperature (RT). (I) *A. fischeri* grown on blood agar at RT. The retention time (3.30 min) and accurate mass ( $327.0473 \pm 5.0$  ppm) data confirm the biosynthesis of gliotoxin by *A. fischeri* in panels F and G. NL, normalization level (i.e., base peak intensity; the larger the NL value the better the signal to noise ratio).

To test whether *A. fischeri* biosynthesized gliotoxin, we grew strain NRRL 181 on the same media and under the same temperature conditions as *A. fumigatus*. When *A. fischeri* was grown on CDA at 37°C, we observed a peak with the same retention time (Fig. 1F), HRESIMS spectrum (Fig. S4), and MS/MS spectrum as those observed when analyzing our *A. fumigatus* extract (Fig. S5), indicating gliotoxin biosynthesis in *A. fischeri*. Similarly, we detected gliotoxin production in lower abundance when we grew *A. fischeri* on 5% blood agar at 37°C (Fig. 1G). In contrast, we did not observe gliotoxin production when we grew *A. fischeri* on CDA or on 5% blood agar at room temperature (Fig. 1H or I, respectively) or on oatmeal agar at 37°C (Fig. S3). These results demonstrate that (ii) the nonpathogen *A. fischeri* biosynthesizes similar quantities of gliotoxin under the same conditions that induce gliotoxin biosynthesis in the major pathogen *A. fumigatus* and (ii) as with what has previously been observed in *A. fumigatus* (21, 22), both growth medium and temperature influence gliotoxin biosynthesis in *A. fischeri*.

***laeA*, a master regulator of secondary metabolism and *A. fumigatus* virulence factor, is not a virulence factor in *A. fischeri*.** To test whether the regulation of secondary metabolite production contributes to the virulence profile of *A. fischeri*, we deleted the endogenous copy of *laeA* from *A. fischeri* and infected larvae of the moth



**FIG 2** Deletion of the master regulator *laeA* in *A. fischeri* does not alter its virulence. Cumulative survivals of moth (*Galleria mellonella*) larvae inoculated with  $5 \times 10^5$  (left) or  $1 \times 10^6$  (right) asexual spores or conidia of either the  $\Delta laeA$  mutant or the wild-type (WT) *A. fischeri* NRRL 181 strain are shown. Comparisons of moth cumulative survival when infected with either the  $\Delta laeA$  or WT strain revealed no statistically significant differences at spore concentrations of  $5 \times 10^5$  (left) or  $1 \times 10^6$  (right) ( $P$  value = 0.91 and 0.30, respectively; log-rank test). For the inoculations, 10 moths were infected per group.

*Galleria mellonella*, a well-established invertebrate model of fungal disease (23), with the resulting mutant strain (unpublished data). The use of *G. mellonella* larvae is an appropriate model for our study for two reasons. First, our previous work revealed consistent virulence profile differences between wild-type (WT) strains of *A. fischeri* and *A. fumigatus* in two different murine models and in *G. mellonella* moth larvae (14). Second, infection of *G. mellonella* larvae with *A. fumigatus* is known to induce gliotoxin biosynthesis (24). We infected asexual spores (conidia) at two different concentrations and compared the survival curves between the  $\Delta laeA$  mutant and the WT strain of *A. fischeri* (Fig. 2). At both concentrations, our experiments showed that levels of moth larval survival were not significantly different between the  $\Delta laeA$  and WT strains.

Importantly, the  $\Delta laeA$  strain of *A. fischeri* NRRL 181 is known to exhibit reduced production of secondary metabolites under diverse conditions in a manner consistent with the gene's role as a master regulator of secondary metabolism (14). To confirm that the  $\Delta laeA$  strain does not produce gliotoxin, we analyzed it using the same chemical methods that showed the production of gliotoxin in the WT strain following growth on CDA or 5% blood agar at 37°C. Unlike with the WT strain (Fig. 1F and G), we did not observe gliotoxin production in the  $\Delta laeA$  strain (Fig. S3). Although the losses of *laeA* and secondary metabolite, including gliotoxin, production have previously been shown to reduce the virulence of the major pathogen *A. fumigatus* (11, 12), our results suggest that the losses of *laeA* and secondary metabolite production (14) in *A. fischeri* do not influence its virulence.

Deletion of *laeA* (11, 12) and *gliP* (8–10) results in the attenuation of *A. fumigatus* virulence; in contrast, deletion or overexpression of *gliZ*, the transcriptional regulator of the gliotoxin biosynthetic cluster, does not alter the virulence of *A. fumigatus* (25). Dissecting the effect of gliotoxin in *A. fischeri* virulence through the construction of  $\Delta gliZ$  and  $\Delta gliP$  mutants in multiple animal models would be an interesting follow-up experiment, especially given that *A. fumigatus*  $\Delta laeA$  strains have previously been shown to produce a lower, but considerable, amount of gliotoxin *in vivo* during murine infection (25). However, given that the deletion of *laeA* does not alter *A. fischeri* virulence (Fig. 2), the expectation is that specific inactivation of the gliotoxin biosynthetic gene cluster would not alter the virulence profile of *A. fischeri*.

**Concluding remarks.** In this study, we show for the first time that *A. fischeri*, when grown under conditions known to induce gliotoxin production in *A. fumigatus*, can biosynthesize gliotoxin (Fig. 1). Furthermore, we show that an *A. fischeri* mutant that lacks a master regulatory gene of secondary metabolism (*laeA*) does not alter the pathogenic potential of *A. fischeri* (Fig. 2). Thus, it appears that secondary metabolites are virulence factors in the genomic and phenotypic background of the pathogen *A. fumigatus* but that they are much less important for virulence in the genomic back-

ground of the nonpathogen *A. fischeri*. These results provide support for the “cards of virulence” model of opportunistic fungal disease (26), in which the ability to cause disease stems from the combination (“hand”) of individual virulence factors (“cards”). We hypothesize that while *A. fischeri* possesses the cards for gliotoxin production and secondary metabolism regulation, its cumulative hand is thankfully not a winner when it comes to causing disease.

**Fungal strains.** *Aspergillus fischeri* strain NRRL 181 was obtained from the ARS Culture Collection (NRRL) (14). *A. fumigatus* strain Af293 was also utilized as a positive control (27).

**Growth conditions.** All strains were maintained on potato dextrose agar (PDA; Difco). To establish individual cultures, an agar square along with fungal mycelium was cut out aseptically from the leading edge of the culture and transferred onto blood agar (tryptic soy agar with 5% sheep’s blood; Hardy Diagnostics), Czapek-Dox agar (CDA; Difco), or oatmeal agar (OMA; Difco). All cultures at 37°C were maintained in an incubator (VWR International) in the dark for 4 days. All cultures at room temperature (RT; ~22°C) were kept for 2 weeks under a 12-h light/12-h dark cycle. *A. fischeri* was grown on CDA (RT and 37°C), blood agar (RT and 37°C), and OMA (37°C). *A. fumigatus* was grown on CDA (37°C), blood agar (37°C), and OMA (37°C).

**Extraction.** To evaluate the biosynthesis of gliotoxin in these fungal strains, cultures were extracted with organic solvents and analyzed by mass spectrometry (see below). The fungus was extracted from agar plates by spraying the fungal mycelium with methanol (MeOH), chopping it with a spatula, and transferring the contents to a scintillation vial. Acetone (~15 ml) was then added to the scintillation vial, and the resulting slurry was vortexed vigorously for approximately 3 min before being steeped for 4 h at RT. Subsequently, the mixture was filtered, and the resulting material was dried under a stream of nitrogen gas to yield the dried organic extract. Solid medium was prepared and extracted as reported previously (14).

**UHPLC-HRESIMS analysis.** High-resolution electrospray ionization mass spectrometry (HRESIMS) experiments utilized a Thermo LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientific), equipped with an electrospray ionization source. This was coupled to an Acquity ultrahigh-performance liquid chromatography (UHPLC) system (Waters Corp.), using a flow rate of 0.3 ml/min and a bridged ethylene hybrid C<sub>18</sub> column (2.1 mm by 50 mm, 1.7 μm) that was operated at 40°C. The mobile phase consisted of CH<sub>3</sub>CN-H<sub>2</sub>O (Fischer Optima LC-MS grade; both were acidified with 0.1% formic acid). The gradient began at 15% CH<sub>3</sub>CN and increased linearly to 100% CH<sub>3</sub>CN over 8 min, at which point it was held for 1.5 min before it was returned to starting conditions to reequilibrate.

Extracts were analyzed in the positive-ion mode, with scanning over a mass range of *m/z* 100 to 2,000 at a resolving power of 30,000. The spray voltage, source capillary, and tube lens voltages were set to 4.0 kV, 20 V, and 100 V, respectively, with a nitrogen sheath gas set to 30 arbitrary units (arb) and a capillary temperature at 300°C. The fragmentation patterns (i.e., MS/MS data) were obtained by using an inclusion list containing the mass of gliotoxin ( $[M+H]^+ = 327.047$  *m/z*), with an isolation window of 2 Da and a collision energy of 35%. The dried organic extracts and gliotoxin standard (Cayman Chemical Company) were prepared in MeOH at a concentration of 0.2 mg/ml and 0.01 mg/ml, respectively, with an injection volume of 3 μl. To eliminate the possibility for sample carryover, two blanks (MeOH) were injected between every sample injection, and the gliotoxin standard was analyzed at the end of the run.

**Virulence studies using an invertebrate model of fungal disease (*Galleria mellonella*).** Virulence experiments were performed as previously described (14). Briefly, larvae of the moth *G. mellonella* were obtained by breeding adult moths (23) and selecting larvae that were similar in size (~275 to 330 mg). Prior to use, all larvae were kept for 24 h in glass petri dishes in darkness at 37°C. Asexual spores (conidia) of  $\Delta$ *laeA* mutant or the wild-type (WT) *A. fischeri* strains were obtained by growing the

organism on a yeast extract-agar-glucose (YAG) medium for 2 days. Conidia were harvested in phosphate-buffered saline (PBS) and filtered through Miracloth (Calbiochem). Conidial concentration was estimated using a hemocytometer, and conidial viability was assessed through incubation on YAG medium at 37°C for 48 h.

For infection assays, 10 *G. mellonella* larvae in the final (sixth) instar larval stage of development were used per condition. Each larva in the test group was infected with a 5- $\mu$ l inoculum of conidia from the  $\Delta$ *laeA* mutant of *A. fischeri* (at a concentration of either  $5 \times 10^5$  spores/ $\mu$ l or  $1 \times 10^6$  spores/ $\mu$ l), whereas each larva in the control group was inoculated with the same concentration of the WT strain of *A. fischeri*. All inoculations were done using a Hamilton syringe (7000.5KH). All injections were performed at the hemocoel of each larva via the last left proleg. Following inoculation, all larvae were incubated in glass petri dishes in darkness at 37°C. Larval killing was scored daily. Larvae were considered dead if they did not move in response to touch.

## SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

**FIG S1**, DOCX file, 0.4 MB.

**FIG S2**, DOCX file, 0.3 MB.

**FIG S3**, DOCX file, 0.2 MB.

**FIG S4**, DOCX file, 0.3 MB.

**FIG S5**, DOCX file, 0.3 MB.

## ACKNOWLEDGMENTS

Computational infrastructure was provided by The Advanced Computing Center for Research and Education (ACCRE) at Vanderbilt University.

S.L.K. was supported by the National Center for Complementary and Integrative Health, a component of the National Institutes of Health, under award number F31 AT010558. M.E.M. and A.R. were supported by a Vanderbilt University Discovery Grant; J.L.S. and A.R. were supported by the Howard Hughes Medical Institute through the James H. Gilliam Fellowships for Advanced Study program. Research in A.R.'s lab is also supported by the National Science Foundation (grant DEB-1442113), the Guggenheim Foundation, and the Burroughs Wellcome Fund. G.H.G. and L.P.S. were supported by grants from the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP 2016/07870-9 and 2016/21392-2) and the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), both from Brazil.

## REFERENCES

- Bongomin F, Gago S, Oladele RO, Denning DW. 2017. Global and multi-national prevalence of fungal diseases—estimate precision. *J Fungi (Basel)* 3:57. <https://doi.org/10.3390/jof3040057>.
- Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. 2012. Hidden killers: human fungal infections. *Sci Transl Med* 4:165rv13. <https://doi.org/10.1126/scitranslmed.3004404>.
- Raffa N, Keller NP. 2019. A call to arms: mustering secondary metabolites for success and survival of an opportunistic pathogen. *PLoS Pathog* 15:e1007606. <https://doi.org/10.1371/journal.ppat.1007606>.
- Gardiner DM, Howlett BJ. 2005. Bioinformatic and expression analysis of the putative gliotoxin biosynthetic gene cluster of *Aspergillus fumigatus*. *FEMS Microbiol Lett* 248:241–248. <https://doi.org/10.1016/j.femsle.2005.05.046>.
- Dolan SK, O'Keefe G, Jones GW, Doyle S. 2015. Resistance is not futile: gliotoxin biosynthesis, functionality and utility. *Trends Microbiol* 23: 419–428. <https://doi.org/10.1016/j.tim.2015.02.005>.
- Schrettl M, Carberry S, Kavanagh K, Haas H, Jones GW, O'Brien J, Nolan A, Stephens J, Fenelon O, Doyle S. 2010. Self-protection against gliotoxin—a component of the gliotoxin biosynthetic cluster, GliT, completely protects *Aspergillus fumigatus* against exogenous gliotoxin. *PLoS Pathog* 6:e1000952. <https://doi.org/10.1371/journal.ppat.1000952>.
- Lewis RE, Wiederhold NP, Chi J, Han XY, Komanduri KV, Kontoyiannis DP, Prince RA. 2005. Detection of gliotoxin in experimental and human aspergillosis. *Infect Immun* 73:635–637. <https://doi.org/10.1128/IAI.73.1.635-637.2005>.
- Sugui JA, Pardo J, Chang YC, Zarembek KA, Nardone G, Galvez EM, Mullbacher A, Gallin JI, Simon MM, Kwon-Chung KJ. 2007. Gliotoxin is a virulence factor of *Aspergillus fumigatus*: *gliP* deletion attenuates virulence in mice immunosuppressed with hydrocortisone. *Eukaryot Cell* 6:1562–1569. <https://doi.org/10.1128/EC.00141-07>.
- Spikes S, Xu R, Nguyen CK, Chamilos G, Kontoyiannis DP, Jacobson RH, Ejzykiewicz DE, Chiang LY, Filler SG, May GS. 2008. Gliotoxin production in *Aspergillus fumigatus* contributes to host-specific differences in virulence. *J Infect Dis* 197:479–486. <https://doi.org/10.1086/525044>.
- Cramer RA, Jr, Gamcsik MP, Brooking RM, Najvar LK, Kirkpatrick WR, Patterson TF, Balibar CJ, Graybill JR, Perfect JR, Abraham SN, Steinbach WJ. 2006. Disruption of a nonribosomal peptide synthetase in *Aspergillus fumigatus* eliminates gliotoxin production. *Eukaryot Cell* 5:972–980. <https://doi.org/10.1128/EC.00049-06>.
- Bok JW, Balajee SA, Marr KA, Andes D, Nielsen KF, Frisvad JC, Keller NP. 2005. *laeA*, a regulator of morphogenetic fungal virulence factors. *Eukaryot Cell* 4:1574–1582. <https://doi.org/10.1128/EC.4.9.1574-1582.2005>.
- Perrin RM, Fedorova ND, Bok JW, Cramer RA, Wortman JR, Kim HS, Nierman WC, Keller NP. 2007. Transcriptional regulation of chemical diversity in *Aspergillus fumigatus* by *laeA*. *PLoS Pathog* 3:e50. <https://doi.org/10.1371/journal.ppat.0030050>.

13. Sugui JA, Peterson SW, Figat A, Hansen B, Samson RA, Mellado E, Cuenca-Estrella M, Kwon-Chung KJ. 2014. Genetic relatedness versus biological compatibility between *Aspergillus fumigatus* and related species. *J Clin Microbiol* 52:3707–3721. <https://doi.org/10.1128/JCM.01704-14>.
14. Mead ME, Knowles SL, Raja HA, Beattie SR, Kowalski CH, Steenwyk JL, Silva LP, Chiaratto J, Ries LNA, Goldman GH, Cramer RA, Oberlies NH, Rokas A. 2019. Characterizing the pathogenic, genomic, and chemical traits of *Aspergillus fischeri*, a close relative of the major human fungal pathogen *Aspergillus fumigatus*. *mSphere* 4:e00018-19. <https://doi.org/10.1128/mSphere.00018-19>.
15. Hubka V, Barrs V, Dudová Z, Sklenář F, Kubátová A, Matsuzawa T, Yaguchi T, Horie Y, Nováková A, Frisvad JC, Talbot JJ, Kolařík M. 2018. Unravelling species boundaries in the *Aspergillus viridinutans* complex (section *Fumigati*): opportunistic human and animal pathogens capable of interspecific hybridization. *Persoonia* 41:142–174. <https://doi.org/10.3767/persoonia.2018.41.08>.
16. Lonial S, Williams L, Carrum G, Ostrowski M, McCarthy P, Jr. 1997. *Neosartorya fischeri*: an invasive fungal pathogen in an allogeneic bone marrow transplant patient. *Bone Marrow Transplant* 19:753–755. <https://doi.org/10.1038/sj.bmt.1700715>.
17. Coriglione G, Stella G, Gafa L, Spata G, Oliveri S, Padhye AA, Ajello L. 1990. *Neosartorya fischeri* var *fischeri* (Wehmer) Malloch and Cain 1972 (anamorph: *Aspergillus fischerianus* Samson and Gams 1985) as a cause of mycotic keratitis. *Eur J Epidemiol* 6:382–385. <https://doi.org/10.1007/bf00151712>.
18. Bok JW, Keller NP. 2004. LaeA, a regulator of secondary metabolism in *Aspergillus* spp. *Eukaryot Cell* 3:527–535. <https://doi.org/10.1128/ec.3.2.527-535.2004>.
19. Frisvad JC, Larsen TO. 2015. Extrrolites of *Aspergillus fumigatus* and other pathogenic species in *Aspergillus* section *Fumigati*. *Front Microbiol* 6:1485. <https://doi.org/10.3389/fmicb.2015.01485>.
20. Pena GA, Monge MP, Gonzalez Pereyra ML, Dalcerro AM, Rosa CA, Chiacchiera SM, Cavaglieri LR. 2015. Gliotoxin production by *Aspergillus fumigatus* strains from animal environment. Micro-analytical sample treatment combined with a LC-MS/MS method for gliotoxin determination. *Mycotoxin Res* 31:145–150. <https://doi.org/10.1007/s12550-015-0225-7>.
21. Belkacemi L, Barton RC, Hopwood V, Evans EG. 1999. Determination of optimum growth conditions for gliotoxin production by *Aspergillus fumigatus* and development of a novel method for gliotoxin detection. *Med Mycol* 37:227–233. <https://doi.org/10.1080/j.1365-280X.1999.00225.x>.
22. Kosalec I, Pepeljnjak S, Jandrlić M. 2005. Influence of media and temperature on gliotoxin production in *Aspergillus fumigatus* strains. *Arh Hig Rada Toksikol* 56:269–273.
23. Fuchs BB, O'Brien E, Khoury JBE, Mylonakis E. 2010. Methods for using *Galleria mellonella* as a model host to study fungal pathogenesis. *Virulence* 1:475–482. <https://doi.org/10.4161/viru.1.6.12985>.
24. Reeves EP, Messina CG, Doyle S, Kavanagh K. 2004. Correlation between gliotoxin production and virulence of *Aspergillus fumigatus* in *Galleria mellonella*. *Mycopathologia* 158:73–79. <https://doi.org/10.1023/b:myco.0000038434.55764.16>.
25. Bok JW, Chung D, Balajee SA, Marr KA, Andes D, Nielsen KF, Frisvad JC, Kirby KA, Keller NP. 2006. GliZ, a transcriptional regulator of gliotoxin biosynthesis, contributes to *Aspergillus fumigatus* virulence. *Infect Immun* 74:6761–6768. <https://doi.org/10.1128/IAI.00780-06>.
26. Casadevall A. 2006. Cards of virulence and the global virulome for humans. *Microbe* 1:359–364. <https://doi.org/10.1128/microbe.1.359.1>.
27. Nierman WC, Pain A, Anderson MJ, Wortman JR, Kim HS, Arroyo J, Berriman M, Abe K, Archer DB, Bermejo C, Bennett J, Bowyer P, Chen D, Collins M, Coulsen R, Davies R, Dyer PS, Farman M, Fedorova N, Fedorova N, Feldblyum TV, Fischer R, Fosker N, Fraser A, García JL, García MJ, Goble A, Goldman GH, Gomi K, Griffith-Jones S, Gwilliam R, Haas B, Haas H, Harris D, Horiuchi H, Huang J, Humphray S, Jiménez J, Keller N, Khouri H, Kitamoto K, Kobayashi T, Konzack S, Kulkarni R, Kumagai T, Lafon A, Lafton A, Latgé J-P, Li W, Lord A, et al. 2005. Genomic sequence of the pathogenic and allergenic filamentous fungus *Aspergillus fumigatus*. *Nature* 438:1151–1156. <https://doi.org/10.1038/nature04332>.
28. Fedorova ND, Khaldi N, Joardar VS, Maiti R, Amedeo P, Anderson MJ, Crabtree J, Silva JC, Badger JH, Albarraq A, Angiuoli S, Bussey H, Bowyer P, Cotty PJ, Dyer PS, Egan A, Galens K, Fraser-Liggett CM, Haas BJ, Inman JM, Kent R, Lemieux S, Malavazi I, Orvis J, Roemer T, Ronning CM, Sundaram JP, Sutton G, Turner G, Venter JC, White OR, Whitty BR, Youngman P, Wolfe KH, Goldman GH, Wortman JR, Jiang B, Denning DW, Nierman WC. 2008. Genomic islands in the pathogenic filamentous fungus *Aspergillus fumigatus*. *PLoS Genet* 4:e1000046. <https://doi.org/10.1371/journal.pgen.1000046>.